Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Wilkinson E.J., Teixeira M.R. Tumors of the vulva. In: Pathology and genetics of tumors of the breast and female genital organs. Ed. by F.A. Tavassoli, P. Devilee. Lyon: IARC Press, 2003. Pp. 314–334.
  2. Oonk M.H.M., Planchamp F., Baldwin P. et al. European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer. Int J Gynecol Cancer. 2017;27(4):832–7.
  3. Hacker N.F. Vulvar cancer. In: Berek and Hacker’s gynecologic oncology. Ed. by J.S. Berek, N.F. Hacker. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2009. Pp. 536–575.
  4. Ашрафян Л.А., Харченко Н.В., Киселев В.И. и др. Рак вульвы: этиопатогенетическая концепция. М.: Молодая гвардия, 2006. С. 7–38.
  5. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7–30.
  6. WHO classification of tumours of female reproductive organs. Ed. by R.J. Kurman, M.L. Carcangiu, C.S. Herrington, R.H. Young. IARC: Lyon 2014.
  7. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2018.
  8. Коржевская Е.В., Кузнецов В.В. Рак вульвы. Клиническая онкогинекология. Руководство для врачей. Под ред. В.П. Козаченко. 2-е изд., перераб. и доп. М.: Бином, 2016. С. 72–96.
  9. Кузнецов В.В., Коржевская Е.В. Плоскоклеточный рак вульвы. Рациональная фармакотерапия в онкологии. Руководство для практикующих врачей. Под общ. ред. М.И. Давыдова, В.А. Горбуновой. М.: Литтерра, 2015. С. 441–444.
  10. Slomovitz B.M., Coleman R.L., Oonk M.H. et al. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol 2015;138:472–7.
  11. Kamran M.W., O’Toole F., Meghen K. et al. Whole-body [18F]fluoro-2deoxyglucose positron emission tomography scan as combined PETCT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis. Eur J Gynaecol Oncol 2014;35:230–5.
  12. Koh WJ et al. Vulvar Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. / https://www.nccn.org/professionals/physician_gls/pdf/vulvar_blocks.pdf
  13. Moore D.H., Ali S., Koh W.J. et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol 2012;124(3):529–33.
  14. Petereit D.G., Mehta M.P., Buchler D.A., Kinsella T.J. Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 1993;27:963–7.
  15. Hallak S., Ladi L., Sorbe B. Prophylactic inguinal-femoral irradiation as an alternative to primary lymphadenectomy in treatment of vulvar carcinoma. Int J Oncol 2007;31:1077–85.
  16. Mahner S., Jueckstock J., Hilpert F.J. et. al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. Natl Cancer Inst 2015;107(3).
  17. Byfield J.E., Calabro-Jones P., Klisak I., Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X-rays. Int J Radiat Oncol Biol Phys 1982;8(11):1923–33.
  18. Moore D.H., Thomas G.M., Montana G.S. et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:79–85.
  19. Thomas G., Dembo A., DePetrillo A. et al. Concurrent radiation and chemotherapy in vulvar carcinoma. Gynecol Oncol 1989;34(3):263–7.
  20. Wahlen S.A., Slater J.D., Wagner R.J. et al. Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva. Cancer 1995;75:2289–94.
  21. Sebag-Montefiore D.J., McLean C., Arnott S.J. et al. Treatment of advanced carcinoma of the vulvawith chemoradiotherapy – can exenterative surgery be avoided? Int J Gynecol Cancer 1994;4:150–5.
  22. Mell L.K., Mundt A.J., Survey of IMRT use in the United States, 2004. Cancer 2005;104:1296–303.
  23. Lim K., Small W., Pertelance L. et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2011;79:348–55.
  24. Raspagliesi F et al. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva./ J Gynecol Oncol. 2014 Jan;25(1):22- 9. doi: 10.3802/jgo.2014.25.1.22. Epub 2014 Jan 8
  25. Raitanen M., Rantanen V., Kulmala J. et al. Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines Int J Cancer 2002;97:853–7.
  26. Raitanen M., Rantanen V., Kulmala J. et al. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. Int J Cancer 2002;100:238–43.
  27. Gill B.S., Bernard M.E., Lin J.F. et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: a National Cancer Data Base (NCDB) analysis. Gynecol Oncol 2015;137(3):365–72.
  28. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015;22(13):4117–23.
  29. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatmentrelated morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92:715–27.
  30. Nilsson H., Angerås U., Bock D. et al. Is preoperative physical activity related to post- surgery recovery? BMJ Open 2016;6(1):e007997.
  31. Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 2017;39:156–62.
  32. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015;22(13):4117–23.
  33. Carter J. Fast-track surgery in gynaecology and gynaecologic oncology: a review of a rolling clinical audit. ISRN Surgery 2012;2012:368014.
  34. Nelson G., Bakkum-Gamez J., Kalogera E. et al Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations – 2019 update. Int J Gynecol Cancer 2019 Mar 15.
  35. De Almeida E.P.M., De Almeida J.P., Landoni G. et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Br J Anaesth 2017;119(5):900–7.
  36. Wren S.M., Martin M., Yoon J.K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward. J Am Coll Surg 2010;210(4):491–5.
  37. Peedicayil A., Weaver A., Li X. et al. Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol 2011;121(1):64–9.
  38. Swarm R., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2010;8:1046–86.
  39. Ben-Arye E., Samuels N., Lavie O. Integrative medicine for female patients with gynecologic cancer. J Altern Complement Med 2018;24(9–10):881–9.
  40. Goerling U., Jaeger C., Walz A. et al. The efficacy of psycho-oncological interventions for women with gynaecological cancer: a randomized study. Oncology 2014;87:114–24.
  41. Smits A., Lopes A., Bekkers R. et al. Body mass index and the quality of life of endometrial cancer survivors – a systematic review and meta-analysis. Gynecol Oncol 2015;137:180–7.
  42. Schmitz K.H., Courneya K.S., Matthews C. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010;42:1409– 26.
  43. Zhou Y., Chlebowski R., LaMonte M.J. et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women"s Health Initiative. Gynecol Oncol 2014;133(1):4–10.
  44. Biglia N., Zanfagnin V., Daniele A. et al. Lower body lymphedema in patients with gynecologic cancer. Anticancer Res 2017;37(8):4005–15.
  45. Oonk. M. H.M. et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer/ Int J Gynecol Cancer 2017;27: 832Y837
  46. Amant, F., Nooij, L., Annibali, D., van Rompuy, A.-S., Han, S., van den Bulck, H., & Goffin, F. (2018). Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer. Gynecologic and Obstetric Investigation, 1– 7. doi:10.1159/000487435
  47. Witteveen P.O.et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group)./ Ann Oncol. 2009 Sep;20(9):1511-6. doi: 10.1093/annonc/mdp043. Epub 2009
  48. Shields LBE, Gordinier ME Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature./ Gynecol Obstet Invest. 2019;84(1):94- 98. doi: 10.1159/000491090. Epub 2018
  49. Santeufemia D. A. Et al. Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases./ Eur J Gynaecol Oncol. 2012; 33(4): 421– 422
  50. Peri M. A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression/Case Reports in Oncological Medicine Volume 2019, Article ID 1018492, 4 pages https://doi.org/10.1155/2019/1018492
  51. Rose PG et al Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer./ N Engl J Med. 1999 Apr 15;340(15):1144-53
  52. Minig L. Clinical outcomes after fast-track care in women undergoing laparoscopic hysterectomy/ Int J Gynaecol Obstet. 2015 Dec;131(3):301-4. doi: 10.1016/j.ijgo.2015.06.034. Epub 2015 Sep 8
  53. Borman Р. Lymphedema diagnosis, treatment, and follow-up from the view point of physical medicine and rehabilitation specialists. Turk J Phys Med Rehab 2018;64(3):179−97.
  54. Shimizu A et al. Direct oral anticoagulants are effective and safe for the treatment of venous thromboembolism associated with gynecological cancers./ Int J Gynaecol Obstet. 2019 Nov;147(2):252-257. doi: 10.1002/ijgo.12944. Epub 2019 Aug 29
  55. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655
  56. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. edn. Edited by MacLeod C. New York: Columbia University Press; 1949: 191-205
  57. Raspagliesi F. et al. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. J Gynecol Oncol. 2014 Jan;25(1):22- 29. https://doi.org/10.3802/jgo.2014.25.1.22
  58. Bellati F.,et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases (2005) Gynecologic Oncology, 96 (1), pp. 227-231.
  59. Long HJ., et al. “Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study”. Journal of Clinical Oncology 23.21 (2005): 4626-4633.
  60. Rose PG., et al. “Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study”. Journal of Clinical Oncology 17.9 (1999): 2676-2680.
  61. Lepori S, Fontanella C, Maltese G et al. Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma. Annals of Oncology, 2017, 28: mdx372.053.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу